Zura Bio (NASDAQ:ZURA) Shares Up 11.8% - What's Next?

Key Points

• Zura Bio shares climbed 11.8% in mid-day trading to about $6.54, although trading volume was 69% below the average session volume.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $17, with recent targets raised to $20 and $22. One firm, however, maintains a sell rating.
• The clinical-stage biotechnology company reported a quarterly loss of $0.21 per share, while analysts expect a full-year loss of $0.81 per share. Institutional investors own approximately 61.14% of the company.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report)'s stock price rose 11.8% during mid-day trading on Monday . The stock traded as high as $5.95 and last traded at $6.5430. Approximately 257,271 shares were traded during trading, a decline of 69% from the average session volume of 830,721 shares. The stock had previously closed at $5.85.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. William Blair assumed coverage on Zura Bio in a research report on Wednesday, July 8th. They set an "outperform" rating on the stock. Wedbush increased their price target on shares of Zura Bio from $15.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Zura Bio in a report on Monday, July 6th. Guggenheim boosted their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Zura Bio from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $17.00.

Zura Bio Price Performance

The stock has a 50-day moving average price of $5.21 and a 200 day moving average price of $5.39. The firm has a market cap of $597.85 million, a price-to-earnings ratio of -5.57 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. As a group, equities research analysts predict that Zura Bio Limited will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in shares of Zura Bio during the second quarter worth approximately $28,000. Allworth Financial LP purchased a new stake in Zura Bio in the 4th quarter valued at $30,000. Scientech Research LLC purchased a new stake in Zura Bio in the 3rd quarter valued at $45,000. AQR Capital Management LLC acquired a new stake in Zura Bio during the 1st quarter worth $72,000. Finally, Bank of America Corp DE boosted its stake in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock worth $103,000 after purchasing an additional 9,966 shares during the period. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source